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ABSTRACT
Introduction: Rectal melanoma is one type of
mucosal melanoma and accounts for fewer than
2% of all mucosal melanomas; it is a rare,
aggressive disease with dismal prognosis.
Case Report: We report a case of rectal
melanoma with metastasis to the upper
gastrointestinal tract (esophagus, stomach, and
duodenum), and a computed tomography scan
found lesions in liver and brain which were
likely to be metastases.
Conclusion: Not all patients are suitable for
treatment.
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INTRODUCTION
Rectal melanoma is a rare disease entity with
less than 2% of all melanomas occurring in the
anorectum, but usually presents with early
metastasis, with up to 38% of patients already
having distant metastases at the time of
diagnosis [1]. It has a very poor prognosis with
a mean survival time of 24 months despite
surgical resection and adjuvant therapies [2].
In this article, we report a case of a patient
with rectal melanoma that appeared on
colonoscopy as an elevated ulcerated tumor at
the posterior side of the rectum. On gastroscopy,
the patient had multiple small black ulcerated
lesions at various sites of the upper
gastrointestinal tract including esophagus,
stomach, and duodenum. Biopsy of these
suspicious lesions revealed that they shared the
same histopathological characteristics as the
rectal tumor. Also, abdominal and pelvic
computed tomography (CT) scans showed
multiple liver lesions. Interestingly, the patient
had a normal colonoscopy 5 months earlier.
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CASE REPORT
A 75-year-old female was referred to the
gastroenterology department for investigation
of iron deficiency anemia (hemoglobin 65 mg/
dL). Her only other issues during her current
presentation included confusion and chronic
constipation. A large rectal mass was found on
digital rectal examination. No skin lesions were
noted on clinical examination.
The patient underwent gastroscopy which
showed multiple black-colored elevated lesions of
2–3 mm diameter in the esophagus, stomach, and
duodenum up to the second part, as well as at least
four volcano-shaped gastric ulcers with sloughed
base (Fig. 1a, b). In addition, a colonoscopy was
conducted, but the scope insertion was limited to
the rectumonlydue topoorpreparation. In spiteof
this, it showed an elevated, hard black-colored
tumor, 2 9 3 cm in size (Fig. 1c). The patient had a
normal colonoscopy only 5 months prior, which
was also undertaken for the investigation of mild
anemia.
The sections of the gastric mucosa showed
solid nests and sheets of malignant cells
infiltrating the lower part of the lamina
propria. Melanin pigment was present within
the cytoplasm of the malignant cells.
Immunoperoxidase staining demonstrated that
the neoplastic cells had positive staining for
human melanoma black (HMB-45) stain
(Fig. 2a, b). Mild cytoplasmic staining was
noted with S100. Negative staining was seen
with AE1/AE3, CK7, and CK20. The sections of
small bowel mucosa showed solid nests and
sheets of malignant cells infiltrating within the
lower part of the lamina propria. Melanin
pigment was present within the cytoplasm of
the malignant cells. Immunoperoxidase stains
showed that the neoplastic cells had positive
staining for HMB-45. Mild cytoplasmic staining
was noted with S100. Negative staining was
seen with AE1/AE3, CK7, and CK20. The
sections showed mostly necrotic fragments.
One of the fragments showed cords of
malignant cells with similar morphology to
those found in the gastric and duodenal
mucosa. Brown pigments were seen within the
cytoplasm. Immunoperoxidase stains showed
that there were neoplastic cells having positive
staining with HMB-45 (Fig. 2c). Mild
cytoplasmic staining was noted with S100.
Negative staining was seen with AE1/AE3,
CK7 and CK20. Thus, the histological and
immunoperoxidase staining features were
consistent with malignant melanoma.
Her brain, abdominal, and pelvic CT scans
showed multiple lesions on the liver, and a mass
(15 9 13 mm) in the right parietal lobe of the
brain. In this particular case, we assume that
rectal tumor is the primary lesion (melanoma)
because it is a large size and solitary, and the
patient has no skin lesions on examination.
The patient was a resident of a nursing home
with multiple co-morbidities, including severe
cognitive impairment and limited mobility,
resulting in a poor quality of life. After
discussion with the family, it was decided not
to undertake further investigations or aggressive
management, and so she was referred to the
palliative care team. Informed consent was
obtained from the patient for being included in
this case report and for publication of the figures.
DISCUSSION
Melanoma in general is a form of cancer that
begins in melanocytes. It may begin in a mole
(cutaneous melanoma), but can also begin in
Fig. 1 Upper gastrointestinal endoscopy and colonoscopy
ﬁndings. a Lesions found on gastroscopy throughout the
upper gastrointestinal tract; b view of lesions found on
gastroscopy at the stomach; and c rectal tumor on
colonoscopy
c
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other tissues, as melanocytes are located in
various anatomical sites including the base of
the epidermis, the eye, epithelia of the nasal
cavity, oropharynx, anus, vagina, and urinary
tract. Cutaneous melanomas are much more
prevalent than noncutaneous melanomas [3].
As rectal histology studies showed that normal
individuals have some melanocytes within the
squamous mucosa of the anal canal distal to the
dentate line, melanomas of the anorectum are
thought to arise from these cells [4], but primary
melanoma in sun-shielded regions, such as the
rectum, merits etiology other than sun
exposure. Factors, such as genetics,
immunosuppression, and viral infections, may
play a role in the etiology of mucosal melanoma
[5].
Primary anorectal melanoma is a rare
and aggressive disease, accounting for
approximately 0.25% of all melanomas [3],
and for 0.5% of all rectal tumors [6]. It is more
predominant among females, usually in their
5th or 6th decade of life [7] and it seems to be
more common among Caucasians [8, 9]. Most
anorectal melanomas present at a late stage
with symptoms similar to other anorectal
disorders, such as bleeding or mass [5, 8]. In a
minority of patients, the lesion is discovered
incidentally during a screening test [10].
Surgery is suggested as being the best
curative treatment for this disease [3]. Wide
local excision combined with adjuvant loco-
regional radiotherapy is preferred when
technically feasible [11]. Abdominoperineal
resection is performed in cases of large tumors
or where the anal sphincter is involved [11].
Data in the literature on the effect of
radiotherapy alone or in combination with
surgery are scarce [12–14]. Bujko et al. [14]
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published a report of three cases in which
radiotherapy was used resulting in long-lasting
control of local symptoms. They observed a
high rate of recurrence in the inguinal lymph
nodes and recommended that the groin lymph
nodes be included in the radiation field [14]. In
an additional case report, Gupta et al. [15]
suggested that interstitial brachytherapy after
Fig. 2 View of lesions found on gastroscopy at the
stomach. a gastric biopsy shows neoplastic cells (left);
gastric biopsy shows melanoma features after human
melanoma black (HMB-45) stain was applied (right);
b duodenum biopsy shows neoplastic cells (left); duodenum
biopsy shows melanoma features after HMB-45 stain was
applied (right); c rectal biopsy shows neoplastic cells (left);
rectal biopsy shows melanoma features after HMB-45 stain
was applied (right)
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local resection of anorectal melanoma may help
to avoid local recurrence.
Nivolumab [16], vemurafenib [17], dabrafenib
[18], trametinib [18], lambrolizumab [19], and
ipilimumab [16] have shown to be promising in
the therapy of advanced melanoma. However,
there isnomention of these agents regarding their
use in treating anorectal melanoma in the
literature. Multiple colonic perforations have
been reported as a fatal complication during
treatment of metastatic melanoma with
ipilimumab [20], and the use of these agents in
patients with anorectal melanoma in the future is
uncertain.
The overall prognosis of anorectal
melanoma remains dismal, despite surgical
resection and emergence of various forms of
adjuvant therapy [21]. However, some
patients when treated by radical resection
may experience long-term survival [4]. The
prognosis of rectal melanoma is largely
related to the stage of disease. The 5-year
survival rate is estimated at about 24% for
patients with stage I tumors, but patients
with stage II and III tumors have appreciably
shorter survival times of 12 months on
average [22]. The overall 5-year survival rate
is less than 20% [21].
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